Table 1.
Baseline demographics and clinical characteristics
| Baricitinib group (n=764) | Placebo group (n=761) | |||
|---|---|---|---|---|
| Age, years | ||||
| Mean (SD) | 57·8 (14·3) | 57·5 (13·8) | ||
| <65 | 508/764 (66%) | 518/761 (68%) | ||
| ≥65 | 256/764 (34%) | 243/761 (32%) | ||
| Sex | ||||
| Male | 490/764 (64%) | 473/761 (62%) | ||
| Female | 274/764 (36%) | 288/761 (38%) | ||
| Race | ||||
| American Indian or Alaskan Native* | 148/752 (20%) | 168/741 (23%) | ||
| Asian | 80/752 (11%) | 94/741 (13%) | ||
| Black or African American | 39/752 (5%) | 36/741 (5%) | ||
| Native Hawaiian or other Pacific Islander | 3/752 (<1%) | 2/741 (<1%) | ||
| White | 480/752 (64%) | 440/741 (59%) | ||
| Multiple | 2/752 (<1%) | 1/741 (<1%) | ||
| Ethnicity† | ||||
| Hispanic or Latino | 54/162 (33%) | 46/158 (29%) | ||
| Not Hispanic or Latino | 92/162 (57%) | 94/158 (59%) | ||
| Not reported | 16/162 (10%) | 18/158 (11%) | ||
| Region and country | ||||
| Europe | 73/764 (10%) | 70/761 (9%) | ||
| Germany | 9/764 (1%) | 11/761 (1%) | ||
| Italy | 15/764 (2%) | 10/761 (1%) | ||
| Spain | 45/764 (6%) | 42/761 (6%) | ||
| UK | 4/764 (1%) | 7/761 (1%) | ||
| USA (including Puerto Rico) | 162/764 (21%) | 158/761 (21%) | ||
| Rest of world | 529/764 (69%) | 533/761 (70%) | ||
| Argentina | 107/764 (14%) | 101/761 (13%) | ||
| Brazil | 172/764 (23%) | 165/761 (22%) | ||
| India | 19/764 (2%) | 31/761 (4%) | ||
| Japan | 19/764 (2%) | 19/761 (2%) | ||
| South Korea | 16/764 (2%) | 20/761 (3%) | ||
| Mexico | 138/764 (18%) | 143/761 (19%) | ||
| Russia | 58/764 (8%) | 54/761 (7%) | ||
| Body-mass index (kg/m2) | 30·4 (6·4) | 30·6 (6·6) | ||
| Duration of disease symptoms before enrolment, days | ||||
| <7 | 137/762 (18%) | 116/756 (15%) | ||
| ≥7 | 625/762 (82%) | 640/756 (85%) | ||
| Score on NIAID-OS | ||||
| 4 (hospitalised, not requiring supplemental oxygen) | 89/762 (12%) | 97/756 (13%) | ||
| 5 (hospitalised, requiring supplemental oxygen) | 490/762 (64%) | 472/756 (62%) | ||
| 6 (hospitalised, receiving non-invasive ventilation or high-flow oxygen) | 183/762 (24%) | 187/756 (25%) | ||
| Concomitant medications of interest | ||||
| Remdesivir | 140/762 (18%) | 147/756 (19%) | ||
| Systemic corticosteroids | 612/762 (80%) | 592/756 (78%) | ||
| Dexamethasone | 566/612 (92%) | 533/592 (90%) | ||
| Pre-existing comorbidities of interest | ||||
| Obesity | 250/764 (33%) | 253/761 (33%) | ||
| Diabetes (types 1 and 2) | 224/764 (29%) | 233/761 (31%) | ||
| Chronic respiratory disease | 34/764 (4%) | 36/761 (5%) | ||
| Hypertension | 365/764 (48%) | 366/761 (48%) | ||
Data are mean (SD) or n/N (%). NIAID-OS=National Institute of Allergy and Infectious Disease Ordinal Scale.
*
Includes participants from Mexico and Latin America.
†
Reporting required in the USA only.